{"id":988238,"date":"2026-08-03T04:54:01","date_gmt":"2026-08-03T08:54:01","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/regeneron-pharmaceuticals-inc-sued-for-securities-law-violations-contact-the-djs-law-group-to-discuss-your-rights-regn-2\/"},"modified":"2026-08-03T04:54:01","modified_gmt":"2026-08-03T08:54:01","slug":"regeneron-pharmaceuticals-inc-sued-for-securities-law-violations-contact-the-djs-law-group-to-discuss-your-rights-regn-2","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/regeneron-pharmaceuticals-inc-sued-for-securities-law-violations-contact-the-djs-law-group-to-discuss-your-rights-regn-2\/","title":{"rendered":"Regeneron Pharmaceuticals, Inc. Sued for Securities Law Violations – Contact the DJS Law Group to Discuss Your Rights – REGN"},"content":{"rendered":"
\n

PR Newswire<\/p>\n<\/p><\/div>\n

\n

\n LOS ANGELES<\/span>, Aug. 3, 2026<\/span> \/PRNewswire\/ — The DJS Law Group<\/a>\u00a0reminds investors of a class action lawsuit against\u00a0Regeneron Pharmaceuticals, Inc. (“Regeneron” or “the Company”) (NASDAQ: REGN<\/a>) violations of \u00a7\u00a710(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.<\/p>\n

Shareholders who purchased shares of REGN during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointments. Appointment as lead plaintiff is not required to partake in any recovery.<\/p>\n

\n CLASS PERIOD:<\/b>\u00a0August 1, 2025 to May 15, 2026<\/p>\n

\n DEADLINE: <\/b>September 14, 2026<\/p>\n

\n CASE DETAILS: <\/b>According to the Complaint, the Company made false and misleading statements to the market. The Company gave investors the impression its Phase III Fianlimab-Libtayo Study showed signs of success and minimized risks presented by the study. The Company’s study ultimately failed to achieve its primary endpoint in a statistically significant manner. Based on these facts, Regeneron’s public statements were false and materially misleading throughout the class period.<\/p>\n

If you are a shareholder who suffered a loss, contact us to participate<\/a>.<\/p>\n

\n WHY DJS LAW GROUP?<\/b>\u00a0DJS Law Group’s primary focus is to enhance investor return through balanced counseling and aggressive advocacy. We specialize in securities class actions, corporate governance litigation, and domestic\/international M&A appraisals. Our clients are some of the largest and most sophisticated hedge funds and alternative asset managers in the world. The litigation claims of our clients are extraordinarily valuable assets that demand respect, focus, and results.<\/p>\n

\n Join the case<\/a>\u00a0to recover your losses.<\/p>\n

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.<\/p>\n

\n CONTACT:<\/b>\n <\/p>\n

David J. Schwartz<\/p>\n

DJS Law Group<\/p>\n

274 White Plains Road, Suite 1<\/p>\n

\u00a0Eastchester, NY 10709<\/p>\n

Phone: 914-206-9742<\/p>\n

Email: David@djslawllp.com<\/a><\/p>\n

\n \"Cision\" View original content:https:\/\/www.prnewswire.com\/news-releases\/regeneron-pharmaceuticals-inc-sued-for-securities-law-violations—contact-the-djs-law-group-to-discuss-your-rights–regn-302840848.html<\/a><\/p>\n

SOURCE DJS Law Group LLP<\/p>\n<\/p><\/div>\n

\"\"<\/p>\n","protected":false},"excerpt":{"rendered":"

PR Newswire LOS ANGELES, Aug. 3, 2026 \/PRNewswire\/ — The DJS Law Group\u00a0reminds investors of a class action lawsuit against\u00a0Regeneron Pharmaceuticals, Inc. (“Regeneron” or “the Company”) (NASDAQ: REGN) violations of \u00a7\u00a710(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Shareholders who purchased shares of REGN during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointments. Appointment as lead plaintiff is not required to partake in any recovery. CLASS PERIOD:\u00a0August 1, 2025 to May 15, 2026 DEADLINE: September 14, 2026 CASE DETAILS: According to the Complaint, the Company made false and misleading statements to the market. The Company gave investors the impression … <\/p>\n

Continue reading “Regeneron Pharmaceuticals, Inc. Sued for Securities Law Violations – Contact the DJS Law Group to Discuss Your Rights – REGN”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-988238","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nRegeneron Pharmaceuticals, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - REGN - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/regeneron-pharmaceuticals-inc-sued-for-securities-law-violations-contact-the-djs-law-group-to-discuss-your-rights-regn-2\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Regeneron Pharmaceuticals, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - REGN - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"PR Newswire LOS ANGELES, Aug. 3, 2026 \/PRNewswire\/ — The DJS Law Group\u00a0reminds investors of a class action lawsuit against\u00a0Regeneron Pharmaceuticals, Inc. (“Regeneron” or “the Company”) (NASDAQ: REGN) violations of \u00a7\u00a710(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Shareholders who purchased shares of REGN during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointments. Appointment as lead plaintiff is not required to partake in any recovery. CLASS PERIOD:\u00a0August 1, 2025 to May 15, 2026 DEADLINE: September 14, 2026 CASE DETAILS: According to the Complaint, the Company made false and misleading statements to the market. The Company gave investors the impression … Continue reading "Regeneron Pharmaceuticals, Inc. Sued for Securities Law Violations – Contact the DJS Law Group to Discuss Your Rights – REGN"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/regeneron-pharmaceuticals-inc-sued-for-securities-law-violations-contact-the-djs-law-group-to-discuss-your-rights-regn-2\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-08-03T08:54:01+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/edge.prnewswire.com\/c\/img\/favicon.png?sn=LA17479&sd=2026-08-03\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/regeneron-pharmaceuticals-inc-sued-for-securities-law-violations-contact-the-djs-law-group-to-discuss-your-rights-regn-2\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/regeneron-pharmaceuticals-inc-sued-for-securities-law-violations-contact-the-djs-law-group-to-discuss-your-rights-regn-2\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Regeneron Pharmaceuticals, Inc. Sued for Securities Law Violations – Contact the DJS Law Group to Discuss Your Rights – REGN\",\"datePublished\":\"2026-08-03T08:54:01+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/regeneron-pharmaceuticals-inc-sued-for-securities-law-violations-contact-the-djs-law-group-to-discuss-your-rights-regn-2\\\/\"},\"wordCount\":327,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/regeneron-pharmaceuticals-inc-sued-for-securities-law-violations-contact-the-djs-law-group-to-discuss-your-rights-regn-2\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/edge.prnewswire.com\\\/c\\\/img\\\/favicon.png?sn=LA17479&sd=2026-08-03\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/regeneron-pharmaceuticals-inc-sued-for-securities-law-violations-contact-the-djs-law-group-to-discuss-your-rights-regn-2\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/regeneron-pharmaceuticals-inc-sued-for-securities-law-violations-contact-the-djs-law-group-to-discuss-your-rights-regn-2\\\/\",\"name\":\"Regeneron Pharmaceuticals, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - REGN - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/regeneron-pharmaceuticals-inc-sued-for-securities-law-violations-contact-the-djs-law-group-to-discuss-your-rights-regn-2\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/regeneron-pharmaceuticals-inc-sued-for-securities-law-violations-contact-the-djs-law-group-to-discuss-your-rights-regn-2\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/edge.prnewswire.com\\\/c\\\/img\\\/favicon.png?sn=LA17479&sd=2026-08-03\",\"datePublished\":\"2026-08-03T08:54:01+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/regeneron-pharmaceuticals-inc-sued-for-securities-law-violations-contact-the-djs-law-group-to-discuss-your-rights-regn-2\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/regeneron-pharmaceuticals-inc-sued-for-securities-law-violations-contact-the-djs-law-group-to-discuss-your-rights-regn-2\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/regeneron-pharmaceuticals-inc-sued-for-securities-law-violations-contact-the-djs-law-group-to-discuss-your-rights-regn-2\\\/#primaryimage\",\"url\":\"https:\\\/\\\/edge.prnewswire.com\\\/c\\\/img\\\/favicon.png?sn=LA17479&sd=2026-08-03\",\"contentUrl\":\"https:\\\/\\\/edge.prnewswire.com\\\/c\\\/img\\\/favicon.png?sn=LA17479&sd=2026-08-03\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/regeneron-pharmaceuticals-inc-sued-for-securities-law-violations-contact-the-djs-law-group-to-discuss-your-rights-regn-2\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Regeneron Pharmaceuticals, Inc. Sued for Securities Law Violations – Contact the DJS Law Group to Discuss Your Rights – REGN\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Regeneron Pharmaceuticals, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - REGN - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/regeneron-pharmaceuticals-inc-sued-for-securities-law-violations-contact-the-djs-law-group-to-discuss-your-rights-regn-2\/","og_locale":"en_US","og_type":"article","og_title":"Regeneron Pharmaceuticals, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - REGN - Market Newsdesk","og_description":"PR Newswire LOS ANGELES, Aug. 3, 2026 \/PRNewswire\/ — The DJS Law Group\u00a0reminds investors of a class action lawsuit against\u00a0Regeneron Pharmaceuticals, Inc. (“Regeneron” or “the Company”) (NASDAQ: REGN) violations of \u00a7\u00a710(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Shareholders who purchased shares of REGN during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointments. Appointment as lead plaintiff is not required to partake in any recovery. CLASS PERIOD:\u00a0August 1, 2025 to May 15, 2026 DEADLINE: September 14, 2026 CASE DETAILS: According to the Complaint, the Company made false and misleading statements to the market. The Company gave investors the impression … Continue reading \"Regeneron Pharmaceuticals, Inc. Sued for Securities Law Violations – Contact the DJS Law Group to Discuss Your Rights – REGN\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/regeneron-pharmaceuticals-inc-sued-for-securities-law-violations-contact-the-djs-law-group-to-discuss-your-rights-regn-2\/","og_site_name":"Market Newsdesk","article_published_time":"2026-08-03T08:54:01+00:00","og_image":[{"url":"https:\/\/edge.prnewswire.com\/c\/img\/favicon.png?sn=LA17479&sd=2026-08-03","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/regeneron-pharmaceuticals-inc-sued-for-securities-law-violations-contact-the-djs-law-group-to-discuss-your-rights-regn-2\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/regeneron-pharmaceuticals-inc-sued-for-securities-law-violations-contact-the-djs-law-group-to-discuss-your-rights-regn-2\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Regeneron Pharmaceuticals, Inc. Sued for Securities Law Violations – Contact the DJS Law Group to Discuss Your Rights – REGN","datePublished":"2026-08-03T08:54:01+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/regeneron-pharmaceuticals-inc-sued-for-securities-law-violations-contact-the-djs-law-group-to-discuss-your-rights-regn-2\/"},"wordCount":327,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/regeneron-pharmaceuticals-inc-sued-for-securities-law-violations-contact-the-djs-law-group-to-discuss-your-rights-regn-2\/#primaryimage"},"thumbnailUrl":"https:\/\/edge.prnewswire.com\/c\/img\/favicon.png?sn=LA17479&sd=2026-08-03","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/regeneron-pharmaceuticals-inc-sued-for-securities-law-violations-contact-the-djs-law-group-to-discuss-your-rights-regn-2\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/regeneron-pharmaceuticals-inc-sued-for-securities-law-violations-contact-the-djs-law-group-to-discuss-your-rights-regn-2\/","name":"Regeneron Pharmaceuticals, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - REGN - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/regeneron-pharmaceuticals-inc-sued-for-securities-law-violations-contact-the-djs-law-group-to-discuss-your-rights-regn-2\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/regeneron-pharmaceuticals-inc-sued-for-securities-law-violations-contact-the-djs-law-group-to-discuss-your-rights-regn-2\/#primaryimage"},"thumbnailUrl":"https:\/\/edge.prnewswire.com\/c\/img\/favicon.png?sn=LA17479&sd=2026-08-03","datePublished":"2026-08-03T08:54:01+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/regeneron-pharmaceuticals-inc-sued-for-securities-law-violations-contact-the-djs-law-group-to-discuss-your-rights-regn-2\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/regeneron-pharmaceuticals-inc-sued-for-securities-law-violations-contact-the-djs-law-group-to-discuss-your-rights-regn-2\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/regeneron-pharmaceuticals-inc-sued-for-securities-law-violations-contact-the-djs-law-group-to-discuss-your-rights-regn-2\/#primaryimage","url":"https:\/\/edge.prnewswire.com\/c\/img\/favicon.png?sn=LA17479&sd=2026-08-03","contentUrl":"https:\/\/edge.prnewswire.com\/c\/img\/favicon.png?sn=LA17479&sd=2026-08-03"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/regeneron-pharmaceuticals-inc-sued-for-securities-law-violations-contact-the-djs-law-group-to-discuss-your-rights-regn-2\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Regeneron Pharmaceuticals, Inc. Sued for Securities Law Violations – Contact the DJS Law Group to Discuss Your Rights – REGN"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/988238","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=988238"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/988238\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=988238"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=988238"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=988238"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}